Results 201 to 210 of about 779,994 (339)
Data Collection and Remote Control of an IoT Electronic Nose Using Web Services and the MQTT Protocol. [PDF]
Pérez-Solano JJ, Ruiz-Canales A.
europepmc +1 more source
AN APPROXIMATION METHOD USING CONTINUOUS MODELS FOR QUEUEING PROBLEMS II : MULTI-SERVER FINITE QUEUE
Teruo Sunaga+2 more
openalex +2 more sources
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton+17 more
wiley +1 more source
DeepUMQA-X: Comprehensive and insightful estimation of model accuracy for protein single-chain and complex. [PDF]
Liu D, Liu J, Wang H, Liang F, Zhang G.
europepmc +1 more source
Transient analysis of M/M/1 queues in discrete time by general server vacations [PDF]
Walter Böhm, S. G. Mohanty
openalex +1 more source
The HADDOCK2.2 Web Server: User-Friendly Integrative Modeling of Biomolecular Complexes.
G. V. Zundert+9 more
semanticscholar +1 more source
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed+8 more
wiley +1 more source
MSTmap Online: enhanced usability, visualization, and accessibility. [PDF]
Mohseni A, Lonardi S.
europepmc +1 more source
A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp+13 more
wiley +1 more source